Trials / Recruiting
RecruitingNCT07375225
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Federico II University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Praluent (Alirocumab) | Alirocumab 300 mg injection |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2026-01-29
- Last updated
- 2026-01-29
Locations
1 site across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07375225. Inclusion in this directory is not an endorsement.